Fig. 4From: Healthcare provider recognition of pregnancy related risks and management considerations in patients with tuberous sclerosis complexa Provider response frequency distribution of recommendation for mTORi use before pregnancy (N = 66) and b Provider recommendations of timeframe for reducing/stopping mTORi (N = 45).Back to article page